Skip to main content

Table 3 ctDNA gene mutations of 16 Fulvestrant second- or higher-line users

From: Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

Covariate

Overall (N = 16)

PFS subgroups

PFS < 6 months (n = 10)

PFS > 6 months (n = 6)

p-value*

PIK3CA

10 (62.50%)

7 (70.00%)

3 (50.00%)

0.61

TP53

4 (25.00%)

3 (30.00%)

1 (16.67%)

1.00

ESR1

2 (12.50%)

2 (20.00%)

0 (0%)

0.50

ERBB2

4 (25.00%)

4 (40.00%)

0 (0%)

0.23

ESR1/ERBB2

6 (37.50%)

6 (60.00%)

0 (0%)

0.03

TP53/ESR1/ERBB2

8 (50.00%)

7 (70.00%)

1 (16.67%)

0.11

  1. According to their PFS lengths, these patients were divided into two subgroups: PFS < 6 months and PFS > 6 months
  2. * p-values were calculated by using Fisher’s exact tests (n < 5) for categorical variables comparison between PFS < 6 months group and PFS > 6 months group
Back to article page